Subtype
Neuroendocrine Carcinoma
CI-CAN-00001275NECExplore in graph →
515 active trials12 approved drugs28 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001275NECExplore in graph →
Clinical trials
1,533 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (213)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05060016 | A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)(DeLLphi-301) | active not recruiting | Phase 2 | 222 | AmgenINDUSTRY | 18 | Jul 22, 2026 | clinicaltrials |
| NCT06131840 | A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors | recruiting | Phase 1 | 914 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 10 | Jul 22, 2026 | clinicaltrials |
| NCT04826341 | A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors | completed | Phase 1 / Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | Jul 21, 2026 | clinicaltrials |
| NCT07253142 | A Phase II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Subjects With Advanced Lung Cancer | recruiting | Phase 2 | 120 | Shanghai Henlius BiotechINDUSTRY | 1 | Jul 21, 2026 | clinicaltrials |
| NCT07559786 | A Multicenter, Open-label, Randomized, Prospective Clinical Study of Adebrelimab Consolidation Therapy for Limited-Stage Small-Cell Lung Cancer (LS-SCLC) Without Progression After Concurrent Chemoradiotherapy(ARL-LS-SCLC) | recruiting | Phase 2 | 200 | Henan Cancer HospitalOTHER_GOV | 1 | Jul 21, 2026 | clinicaltrials |
| NCT02721732 | Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic | active not recruiting | Phase 2 | 157 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT05078047 | Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO(MOIO) | active not recruiting | Phase 3 | 646 | UNICANCEROTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT07712094 | AK112 Combination Therapy as First Line Treatment for Metastatic Digestive System Neuroendocrine Cancer | not yet recruiting | Phase 2 | 56 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT03043872 | Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN)(CASPIAN) | active not recruiting | Phase 3 | 987 | AstraZenecaINDUSTRY | 23 | Jul 16, 2026 | clinicaltrials |
| NCT03892993 | Patient Decision Aid in Supporting Decision-Making About When to Start or Stop New Drugs, Join Clinical Trials, or Continue Active Surveillance in Patients With Medullary Thyroid Cancer and Their Caregivers | recruiting | N/A | 120 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT05100095 | Hypofractionated Radiation Therapy for Merkel Cell Carcinoma | recruiting | Phase 2 | 52 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT01365169 | Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients" | recruiting | N/A | 590 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT05652686 | A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study) | recruiting | Phase 1 / Phase 2 | 203 | Phanes TherapeuticsINDUSTRY | 1 | Jul 15, 2026 | clinicaltrials |
| NCT02734004 | A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.(MEDIOLA) | active not recruiting | Phase 1 / Phase 2 | 264 | AstraZenecaINDUSTRY | 7 | Jul 14, 2026 | clinicaltrials |
| NCT05691465 | Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells | recruiting | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | Jul 14, 2026 | clinicaltrials |
| NCT05747729 | A Single-arm, Open-label, Clinical Trial of Surufatinib/Serplulimab/Platinum/Etoposide in Neuroendocrine Carcinoma. | recruiting | Phase 1 / Phase 2 | 60 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT05889546 | Rapid Autopsy Protocol for Patients With Small Cell Lung Cancer | recruiting | — | 30 | Indiana UniversityOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT05628376 | TRAcking Thoracic Cancer Evolution Through Therapy (Rx) EVO | recruiting | — | 600 | University College, LondonOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT05787587 | A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors | active not recruiting | Phase 1 | 216 | IDEAYA BiosciencesINDUSTRY | 1 | Jul 13, 2026 | clinicaltrials |
| NCT07302347 | A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participants With Merkel Cell Carcinoma (MK-3475-G21/KEYNOTE-G21) | recruiting | Phase 1 / Phase 2 | 20 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Jul 13, 2026 | clinicaltrials |
| NCT07698054 | Toripalimab Combined With Beat Chemotherapy in the Treatment of Advanced Back-line Small Cell Lung Cancer | not yet recruiting | Phase 2 | 130 | Henan Cancer HospitalOTHER_GOV | 0 | Jul 13, 2026 | clinicaltrials |
| NCT02635009 | Whole-Brain Radiation Therapy With or Without Hippocampal Avoidance in Limited Stage or Extensive Stage Small Cell Lung Cancer | completed | Phase 2 / Phase 3 | 418 | NRG OncologyOTHER | 2 | Jul 10, 2026 | clinicaltrials |
| NCT06502977 | Study Evaluating Tarlatamab in Chinese Participants With Advanced Small Cell Lung Cancer After Two or More Prior Lines of Treatment(DeLLphi-307) | active not recruiting | Phase 2 | 32 | AmgenINDUSTRY | 1 | Jul 9, 2026 | clinicaltrials |
| NCT07174583 | A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer | recruiting | Phase 1 / Phase 2 | 262 | IDEAYA BiosciencesINDUSTRY | 1 | Jul 9, 2026 | clinicaltrials |
| NCT04487756 | Combination of Atezolizumab With Dendritic Cell Vaccine in Patients With Lung Cancer(VENEZO-LUNG) | completed | Phase 1 / Phase 2 | 20 | Instituto Oncológico Dr RosellOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT06049966 | Atezolizumab in Large Cell Neuroendocrine Carcinoma(LANCE) | completed | Phase 1 | 22 | Oncology Center of Biochemical Education And ResearchOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT06103682 | LOcally ABLatIve ThErapy for OligopRogressive Lung And Thoracic MalignanciEs (OBLITERATE)(OBLITERATE) | recruiting | N/A | 100 | University of California, DavisOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT07242547 | Study of Tarlatamab as Maintenance Treatment After Chemo-radiotherapy for Limited Stage SCLC Patients(MERLIN) | recruiting | Phase 2 | 37 | Fundación GECPOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT07416695 | A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HLX3901 in Patients With Advanced SCLC or NEC | recruiting | Phase 1 | 138 | Shanghai Henlius BiotechINDUSTRY | 1 | Jul 8, 2026 | clinicaltrials |
| NCT00113360 | RAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma | completed | Phase 2 | 67 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT04745689 | Study of AZD2811 + Durvalumab in ES-SCLC(TAZMAN) | active not recruiting | Phase 2 | 31 | AstraZenecaINDUSTRY | 4 | Jul 6, 2026 | clinicaltrials |
| NCT07358676 | A Study of Bemotuzumab Plus Chemotherapy and Anlotinib Induction Followed by Bemotuzumab, Anlotinib and Consolidative Thoracic Radiotherapy in Extensive-Stage Small Cell Lung Cancer | recruiting | Phase 2 | 25 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT07423585 | Tarlatamab for the Treatment of Extensive Stage Small-cell Lung Cancer | recruiting | Phase 2 | 39 | Asrar AlahmadiOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT07684170 | Study of CTX-471 in Patients With Neural Cell Adhesion Molecule (NCAM) Positive Neuroendocrine Neoplasms | not yet recruiting | Phase 2 | 58 | Compass TherapeuticsINDUSTRY | 0 | Jul 6, 2026 | clinicaltrials |
| NCT07118176 | Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers | active not recruiting | Phase 1 | 30 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT07677787 | DLL3-Targeted PET/CT in Small Cell Lung Cancer | recruiting | N/A | 20 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT02856347 | Prospective Study Evaluating the Medullary Thyroid Cancer Management's Care Using PET F-DOPA in Patients With a High Level of Postoperative Residual Thyrocalcitonin(CMTpostopFDOPA) | completed | N/A | 24 | Institut Claudius RegaudOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT06598306 | Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)(DeLLphi-308) | recruiting | Phase 1 | 220 | AmgenINDUSTRY | 10 | Jun 26, 2026 | clinicaltrials |
| NCT07149363 | Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer | recruiting | Phase 2 | 65 | Alliance Foundation Trials, LLC.OTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT07670442 | Epigenomic Profiling of Circulating Cell-Free DNA (cfDNA) to Characterize the Dynamic Evolution of Molecular Subtypes in Extensive-Stage Small Cell Lung Cancer During First-Line Chemoimmunotherapy(EPICIRC-SCLC) | not yet recruiting | — | 50 | Assistance Publique - Hôpitaux de ParisOTHER | 0 | Jun 26, 2026 | clinicaltrials |
| NCT04975152 | Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma | recruiting | Phase 1 | 36 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT06227546 | MGC018 in Patients With Relapsed or Refractory Extensive-Stage Small-Cell Lung Cancer(MGC018-SCLC) | active not recruiting | Phase 2 | 9 | Georgetown UniversityOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT07215988 | Studying Off Label Insurance Coverage for Patients With Cutaneous Cancers a "Filter" Observational Study | recruiting | — | 70 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT07366658 | Safety, Tolerability and Preliminary Efficacy of NEUK203-13 in Refractory Neuroendocrine Tumor Patients(NEUK203-13) | recruiting | Phase 1 | 9 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT07652736 | A Study to Investigate Treatment Patterns and Effectiveness of Tislelizumab in European Patients With Resectable or Advanced Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC)(TITANS) | recruiting | — | 440 | BeOne MedicinesINDUSTRY | 1 | Jun 25, 2026 | clinicaltrials |
| NCT00887159 | A Randomized Phase II Study of Cisplatin and Etoposide in Combination With Either Hedgehog Inhibitor GDC-0449 or IGF-1R MOAB IMC-A12 for Patients With Extensive Stage | completed | Phase 2 | 168 | National Cancer Institute (NCI)NIH | 1 | Jun 24, 2026 | clinicaltrials |
| NCT01642251 | Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 156 | National Cancer Institute (NCI)NIH | 1 | Jun 24, 2026 | clinicaltrials |
| NCT05368207 | Pembrolizumab in Small Cell Carcinoma of Ovary - Hypercalcemic Type Patient(Pemb-HT) | completed | N/A | 1 | University Health Network, TorontoOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT07046923 | A Study of LY4175408 in Participants With Advanced Cancer | recruiting | Phase 1 | 240 | Eli Lilly and CompanyINDUSTRY | 6 | Jun 23, 2026 | clinicaltrials |
| NCT03110978 | Stereotactic Body Radiation Therapy With or Without Nivolumab in Treating Patients With Stage I-IIA or Recurrent Non-small Cell Lung Cancer | active not recruiting | Phase 2 | 140 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 22, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jul 22, 2026source: clinicaltrials